Brinsupri is an oral, once-daily dipeptidyl peptidase-1 (DPP1) inhibitor for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and adolescents aged 12 years and older. It represents the first FDA-approved targeted therapy for this chronic, progressive lung disease, directly addressing neutrophil-driven inflammation rather than just symptom management.